Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research

New Cleveland Clinic data show that treatment discontinuation and low maintenance doses limit semaglutide’s and tirzepatide’s real-world weight-loss benefits, prompting exploration of four-receptor agonists.